Rivastigmine 3 MG Oral Capsule — RxCUI 312835
RxNorm drug concept · Semantic clinical drug
RxCUI 312835
Semantic clinical drug · SCD
● Current RxNorm concept 40 FDA products
124 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI312835
Official nameRivastigmine 3 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asrivastigmine 3 MG (as rivastigmine tartrate) Oral Capsule; rivastigmine tartrate 3 MG Oral Capsule
FDA products mapped40
Package NDCs mapped124
Reported Medicaid activity (SDUD)5,618 prescriptions · 22 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Rivastigmine: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It's not a cure, and it won't stop the disease from progressing. What it does is help the brain hold on to more of a chemical called acetylcholine, which plays a big role in memory...
- What exactly does rivastigmine do — is it a cure for Alzheimer's or Parkinson's dementia?
- They work through the same mechanism, but they're approved for slightly different things. The patch forms (like Exelon) are approved for mild, moderate, and severe Alzheimer's dise...
- What's the difference between the patch and the capsule — does one work better?
🕸️ Concept Web — How Rivastigmine 3 MG Oral Capsule Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Rivastigmine 3 MG Oral Capsule
RxCUI 312835 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Rivastigmine
183379IN
-
Rivastigmine
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Exelon
225807BN
-
Exelon
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Rivastigmine Oral Capsule
373797SCDF -
Rivastigmine Oral Product
1157971SCDG -
Rivastigmine Pill
1157972SCDG -
Rivastigmine Oral Capsule [Exelon]
366553SBDF -
Exelon Oral Product
1173232SBDG -
Exelon Pill
1173233SBDG -
Oral Capsule
316965DF -
Oral Product
1151131DFG - +1 more in this family
-
Rivastigmine Oral Capsule
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Rivastigmine 3 MG
331509SCDC -
Rivastigmine 3 MG Oral Capsule [Exelon]
226666SBD -
Rivastigmine 3 MG [Exelon]
574013SBDC
-
Rivastigmine 3 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Rivastigmine 3 MG
SCDC · 331509 -
Rivastigmine Oral Capsule
SCDF · 373797 -
Rivastigmine Oral Product
SCDG · 1157971 -
Rivastigmine Pill
SCDG · 1157972
Brand-Name Concepts
-
Rivastigmine 3 MG Oral Capsule [Exelon]
SBD · 226666 -
Rivastigmine 3 MG [Exelon]
SBDC · 574013 -
Rivastigmine Oral Capsule [Exelon]
SBDF · 366553 -
Exelon Oral Product
SBDG · 1173232 -
Exelon Pill
SBDG · 1173233 -
Exelon
BN · 225807
📦 FDA Products & Package NDCs
40 products · 124 package NDCs
124 package NDCs map to RxCUI 312835 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 71209-0012-03 | 60 CAPSULE in 1 BOTTLE (71209-012-03) | Rivastigmine Tartrate | Cadila Pharmaceuticals Limited | 2014-02-11 |
| 71209-0012-10 | 500 CAPSULE in 1 BOTTLE (71209-012-10) | Rivastigmine Tartrate | Cadila Pharmaceuticals Limited | 2014-02-11 |
| 71209-0013-03 | 60 CAPSULE in 1 BOTTLE (71209-013-03) | Rivastigmine Tartrate | Cadila Pharmaceuticals Limited | 2014-02-11 |
| 71209-0013-10 | 500 CAPSULE in 1 BOTTLE (71209-013-10) | Rivastigmine Tartrate | Cadila Pharmaceuticals Limited | 2014-02-11 |
| 71209-0014-03 | 60 CAPSULE in 1 BOTTLE (71209-014-03) | Rivastigmine Tartrate | Cadila Pharmaceuticals Limited | 2014-02-11 |
| 71209-0014-10 | 500 CAPSULE in 1 BOTTLE (71209-014-10) | Rivastigmine Tartrate | Cadila Pharmaceuticals Limited | 2014-02-11 |
| 71209-0015-03 | 60 CAPSULE in 1 BOTTLE (71209-015-03) | Rivastigmine Tartrate | Cadila Pharmaceuticals Limited | 2014-02-11 |
| 71209-0015-10 | 500 CAPSULE in 1 BOTTLE (71209-015-10) | Rivastigmine Tartrate | Cadila Pharmaceuticals Limited | 2014-02-11 |
| 72241-0011-03 | 60 CAPSULE in 1 BOTTLE (72241-011-03) | Rivastigmine Tartrate | Modavar Pharmaceuticals LLC | 2021-10-05 |
| 72241-0011-10 | 500 CAPSULE in 1 BOTTLE (72241-011-10) | Rivastigmine Tartrate | Modavar Pharmaceuticals LLC | 2021-10-05 |
| 72241-0012-03 | 60 CAPSULE in 1 BOTTLE (72241-012-03) | Rivastigmine Tartrate | Modavar Pharmaceuticals LLC | 2021-10-05 |
| 72241-0012-10 | 500 CAPSULE in 1 BOTTLE (72241-012-10) | Rivastigmine Tartrate | Modavar Pharmaceuticals LLC | 2021-10-05 |
| 72241-0013-03 | 60 CAPSULE in 1 BOTTLE (72241-013-03) | Rivastigmine Tartrate | Modavar Pharmaceuticals LLC | 2021-10-05 |
| 72241-0013-10 | 500 CAPSULE in 1 BOTTLE (72241-013-10) | Rivastigmine Tartrate | Modavar Pharmaceuticals LLC | 2021-10-05 |
| 72241-0014-03 | 60 CAPSULE in 1 BOTTLE (72241-014-03) | Rivastigmine Tartrate | Modavar Pharmaceuticals LLC | 2021-10-05 |
| 72241-0014-10 | 500 CAPSULE in 1 BOTTLE (72241-014-10) | Rivastigmine Tartrate | Modavar Pharmaceuticals LLC | 2021-10-05 |
| 75834-0133-05 | 500 CAPSULE in 1 BOTTLE, PLASTIC (75834-133-05) | RIVASTIGMINE TARTRATE | Nivagen Pharmaceuticals, Inc. | 2017-09-04 |
| 75834-0133-60 | 60 CAPSULE in 1 BOTTLE, PLASTIC (75834-133-60) | RIVASTIGMINE TARTRATE | Nivagen Pharmaceuticals, Inc. | 2017-09-04 |
| 75834-0134-05 | 500 CAPSULE in 1 BOTTLE, PLASTIC (75834-134-05) | RIVASTIGMINE TARTRATE | Nivagen Pharmaceuticals, Inc. | 2017-09-04 |
| 75834-0134-60 | 60 CAPSULE in 1 BOTTLE, PLASTIC (75834-134-60) | RIVASTIGMINE TARTRATE | Nivagen Pharmaceuticals, Inc. | 2017-09-04 |
| 75834-0135-05 | 500 CAPSULE in 1 BOTTLE, PLASTIC (75834-135-05) | RIVASTIGMINE TARTRATE | Nivagen Pharmaceuticals, Inc. | 2017-09-04 |
| 75834-0135-60 | 60 CAPSULE in 1 BOTTLE, PLASTIC (75834-135-60) | RIVASTIGMINE TARTRATE | Nivagen Pharmaceuticals, Inc. | 2017-09-04 |
| 75834-0136-05 | 500 CAPSULE in 1 BOTTLE, PLASTIC (75834-136-05) | RIVASTIGMINE TARTRATE | Nivagen Pharmaceuticals, Inc. | 2017-09-04 |
| 75834-0136-60 | 60 CAPSULE in 1 BOTTLE, PLASTIC (75834-136-60) | RIVASTIGMINE TARTRATE | Nivagen Pharmaceuticals, Inc. | 2017-09-04 |
Observed labelers:
Alembic Pharmaceuticals Inc. (20) ·
Alembic Pharmaceuticals Limited (20) ·
Dr. Reddy's Laboratories Limited (16) ·
Macleods Pharmaceuticals Limited (16) ·
Aurobindo Pharma Limited (12) ·
Sun Pharmaceutical Industries, Inc. (12)
· +4 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.